Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

31 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
[2020 oncology update].
Dei Tos G, Galli Vareia I, Huber A, Wolf B, Diciolla A, Herrera Gomez RG, Wagner D, Digklia A, Bouchaab H, Cristina V, Stravodimou A, Zaman K, Sarivalasis A, Berthold D, Peters S, Perrinjaquet C, Kloepper J, Jankovic J. Dei Tos G, et al. Among authors: sarivalasis a. Rev Med Suisse. 2021 Jan 27;17(723):201-205. Rev Med Suisse. 2021. PMID: 33507661 French.
A Phase I/II trial comparing autologous dendritic cell vaccine pulsed either with personalized peptides (PEP-DC) or with tumor lysate (OC-DC) in patients with advanced high-grade ovarian serous carcinoma.
Sarivalasis A, Boudousquié C, Balint K, Stevenson BJ, Gannon PO, Iancu EM, Rossier L, Martin Lluesma S, Mathevet P, Sempoux C, Coukos G, Dafni U, Harari A, Bassani-Sternberg M, Kandalaft LE. Sarivalasis A, et al. J Transl Med. 2019 Nov 26;17(1):391. doi: 10.1186/s12967-019-02133-w. J Transl Med. 2019. PMID: 31771601 Free PMC article.
Quantitative and qualitative impairments in dendritic cell subsets of patients with ovarian or prostate cancer.
Mastelic-Gavillet B, Sarivalasis A, Lozano LE, Wyss T, Inoges S, de Vries IJM, Dartiguenave F, Jichlinski P, Derrè L, Coukos G, Melero I, Harari A, Romero P, Viganó S, Kandalaft LE. Mastelic-Gavillet B, et al. Among authors: sarivalasis a. Eur J Cancer. 2020 Aug;135:173-182. doi: 10.1016/j.ejca.2020.04.036. Epub 2020 Jun 23. Eur J Cancer. 2020. PMID: 32590296 Free article.
Low-Dose Radiotherapy Reverses Tumor Immune Desertification and Resistance to Immunotherapy.
Herrera FG, Ronet C, Ochoa de Olza M, Barras D, Crespo I, Andreatta M, Corria-Osorio J, Spill A, Benedetti F, Genolet R, Orcurto A, Imbimbo M, Ghisoni E, Navarro Rodrigo B, Berthold DR, Sarivalasis A, Zaman K, Duran R, Dromain C, Prior J, Schaefer N, Bourhis J, Dimopoulou G, Tsourti Z, Messemaker M, Smith T, Warren SE, Foukas P, Rusakiewicz S, Pittet MJ, Zimmermann S, Sempoux C, Dafni U, Harari A, Kandalaft LE, Carmona SJ, Dangaj Laniti D, Irving M, Coukos G. Herrera FG, et al. Among authors: sarivalasis a. Cancer Discov. 2022 Jan;12(1):108-133. doi: 10.1158/2159-8290.CD-21-0003. Epub 2021 Sep 3. Cancer Discov. 2022. PMID: 34479871 Free PMC article.
A Personalized Neoantigen Vaccine in Combination with Platinum-Based Chemotherapy Induces a T-Cell Response Coinciding with a Complete Response in Endometrial Carcinoma.
Harari A, Sarivalasis A, de Jonge K, Thierry AC, Huber F, Boudousquie C, Rossier L, Orcurto A, Imbimbo M, Baumgaertner P, Bassani-Sternberg M, Kandalaft LE. Harari A, et al. Among authors: sarivalasis a. Cancers (Basel). 2021 Nov 18;13(22):5801. doi: 10.3390/cancers13225801. Cancers (Basel). 2021. PMID: 34830955 Free PMC article.
[Intraperitoneal therapy for carcinomatosis in ovarian cancer: proposed treatment algorithm].
Undurraga M, Mathevet P, Hubner M, Buchs NC, Warlaumont M, Sarivalasis A, Diciolla A, Lang N, Koessler T, Digklia A, Ris F, Petignat P, Labidi-Galy I. Undurraga M, et al. Among authors: sarivalasis a. Rev Med Suisse. 2022 May 18;18(782):990-996. doi: 10.53738/REVMED.2022.18.782.990. Rev Med Suisse. 2022. PMID: 35583278 Review. French.
31 results